There were two trials with a total of 44 patients. Using data from previous oral studies I will go down on record saying ABT's DAA combination will not provide a sufficient resistance profile without a nucleotide analog backbone.
As Dew would say "you can't make an eagle out of three turkeys."
Market Data 
Markets 
AI
